These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 29936718

  • 1. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
    Azad NA, Shah ZA, Pandith AA, Khan MS, Rasool R, Rasool J, Aziz SA.
    Asian Pac J Cancer Prev; 2018 Jun 25; 19(6):1479-1485. PubMed ID: 29936718
    [Abstract] [Full Text] [Related]

  • 2. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G, GIMEMA CML Working Party.
    Am J Hematol; 2017 Aug 25; 92(8):797-805. PubMed ID: 28466557
    [Abstract] [Full Text] [Related]

  • 3. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
    Pagnano KBB, Miranda EC, Delamain MT, Duarte GO, de Paula EV, Lorand-Metze I, de Souza CA.
    Clin Lymphoma Myeloma Leuk; 2017 Nov 25; 17(11):728-733. PubMed ID: 28822797
    [Abstract] [Full Text] [Related]

  • 4. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
    Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE.
    Haematologica; 2009 Oct 25; 94(10):1362-7. PubMed ID: 19713230
    [Abstract] [Full Text] [Related]

  • 5. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
    Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC, SAKK and the German CML Study Group.
    Haematologica; 2014 Sep 25; 99(9):1441-7. PubMed ID: 24837466
    [Abstract] [Full Text] [Related]

  • 6. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 7. Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India.
    Sazawal S, Chhikara S, Singh K, Chaubey R, Mahapatra M, Seth T, Saxena R.
    Indian J Pathol Microbiol; 2019 Sep 05; 62(2):256-260. PubMed ID: 30971550
    [Abstract] [Full Text] [Related]

  • 8. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.
    J Cancer Res Clin Oncol; 2017 May 05; 143(5):843-850. PubMed ID: 28083711
    [Abstract] [Full Text] [Related]

  • 9. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A, Eskazan AE.
    Cancer; 2018 Oct 01; 124(19):3806-3818. PubMed ID: 29694669
    [Abstract] [Full Text] [Related]

  • 10. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
    Vasconcelos AP, Azevedo IF, Melo FCBC, Neves WB, Azevedo ACAC, Melo RAM.
    Genet Mol Res; 2017 Apr 20; 16(2):. PubMed ID: 28437552
    [Abstract] [Full Text] [Related]

  • 11. Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients.
    Mir R, Ahmad I, Javid J, Zuberi M, Yadav P, Shazia R, Masroor M, Guru S, Ray PC, Gupta N, Saxena A.
    Indian J Cancer; 2015 Apr 20; 52(3):314-8. PubMed ID: 26905124
    [Abstract] [Full Text] [Related]

  • 12. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
    Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J.
    Blood; 2016 Mar 10; 127(10):1269-75. PubMed ID: 26729897
    [Abstract] [Full Text] [Related]

  • 13. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 14. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
    Khazaal MS, Hamdan FB, Al-Mayah QS.
    Mol Genet Genomic Med; 2019 Aug 15; 7(8):e809. PubMed ID: 31206255
    [Abstract] [Full Text] [Related]

  • 15. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, German CML Study Group.
    PLoS One; 2015 Aug 15; 10(6):e0129648. PubMed ID: 26087013
    [Abstract] [Full Text] [Related]

  • 16. BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
    Paramita DK, Hutajulu SH, Syifarahmah A, Sholika TA, Fatmawati S, Aning S, Sulistyawati D, Wahyuni S, Taroeno-Hariadi KW, Kurnianda J.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1545-1550. PubMed ID: 32592347
    [Abstract] [Full Text] [Related]

  • 17. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
    Auewarakul CU, Huang S, Yimyam M, Boonmoh S.
    Acta Haematol; 2006 Jun 01; 116(2):114-9. PubMed ID: 16914906
    [Abstract] [Full Text] [Related]

  • 18. Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
    Azad NA, Shah ZA, Pandith AA, Rasool R, Jeelani S.
    Biosci Rep; 2018 Oct 31; 38(5):. PubMed ID: 30054431
    [Abstract] [Full Text] [Related]

  • 19. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
    Su YJ, Kuo MC, Chen TY, Wang MC, Yang Y, Ma MC, Lin TL, Lin TH, Chang H, Teng CJ, Hsiao PC, Chen CC, Wang PN, Shih LY.
    Cancer Sci; 2022 Oct 31; 113(10):3518-3527. PubMed ID: 35869805
    [Abstract] [Full Text] [Related]

  • 20. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
    Sharma P, Kumar L, Mohanty S, Kochupillai V.
    Ann Hematol; 2010 Mar 31; 89(3):241-7. PubMed ID: 19714331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.